Bellevue Group’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $104M | Buy |
295,358
+276,869
| +1,497% | +$98.7M | 2.47% | 14 |
|
|
2025
Q4 | $6.05M | Buy |
18,489
+3,501
| +23% | +$1.11M | 0.11% | 72 |
|
|
2025
Q3 | $4.23M | Sell |
14,988
-9,120
| -38% | -$2.64M | 0.09% | 82 |
|
|
2025
Q2 | $6.73M | Sell |
24,108
-56,827
| -70% | -$16.1M | 0.15% | 75 |
|
|
2025
Q1 | $25.2M | Sell |
80,935
-8,305
| -9% | -$2.45M | 0.57% | 41 |
|
|
2024
Q4 | $23.3M | Buy |
89,240
+64,088
| +255% | +$19M | 0.45% | 54 |
|
|
2024
Q3 | $8.1M | Sell |
25,152
-4,376
| -15% | -$1.43M | 0.13% | 93 |
|
|
2024
Q2 | $9.23M | Buy |
29,528
+7,389
| +33% | +$2.17M | 0.15% | 91 |
|
|
2024
Q1 | $6.29M | Sell |
22,139
-12,066
| -35% | -$3.53M | 0.1% | 93 |
|
|
2023
Q4 | $9.85M | Sell |
34,205
-14,268
| -29% | -$3.89M | 0.15% | 85 |
|
|
2023
Q3 | $13M | Buy |
48,473
+21,163
| +77% | +$5.28M | 0.21% | 83 |
|
|
2023
Q2 | $6.06M | Sell |
27,310
-11,057
| -29% | -$2.57M | 0.09% | 99 |
|
|
2023
Q1 | $9.28M | Sell |
38,367
-572
| -1% | -$140K | 0.13% | 95 |
|
|
2022
Q4 | $10.2M | Sell |
38,939
-6,257
| -14% | -$1.68M | 0.14% | 98 |
|
|
2022
Q3 | $10.2M | Sell |
45,196
-5,763
| -11% | -$1.4M | 0.15% | 98 |
|
|
2022
Q2 | $12.4M | Sell |
50,959
-2,841
| -5% | -$696K | 0.18% | 99 |
|
|
2022
Q1 | $13M | Sell |
53,800
-4,350
| -7% | -$999K | 0.15% | 103 |
|
|
2021
Q4 | $13.1M | Buy |
58,150
+24,200
| +71% | +$5.11M | 0.13% | 109 |
|
|
2021
Q3 | $7.22M | Sell |
33,950
-95,630
| -74% | -$22M | 0.07% | 124 |
|
|
2021
Q2 | $31.6M | Sell |
129,580
-46,860
| -27% | -$11.5M | 0.31% | 90 |
|
|
2021
Q1 | $43.9M | Sell |
176,440
-41,550
| -19% | -$9.91M | 0.46% | 71 |
|
|
2020
Q4 | $50.1M | Buy |
217,990
+38,377
| +21% | +$8.85M | 0.57% | 54 |
|
|
2020
Q3 | $45.7M | Buy |
179,613
+11,650
| +7% | +$2.89M | 0.63% | 47 |
|
|
2020
Q2 | $39.6M | Buy |
167,963
+36,390
| +28% | +$8.3M | 0.56% | 48 |
|
|
2020
Q1 | $26.7M | Buy |
131,573
+91,223
| +226% | +$19.9M | 0.52% | 51 |
|
|
2019
Q4 | $9.73M | Sell |
40,350
-17,350
| -30% | -$3.82M | 0.15% | 92 |
|
|
2019
Q3 | $11.2M | Buy |
57,700
+11,100
| +24% | +$2.13M | 0.21% | 81 |
|
|
2019
Q2 | $8.59M | Buy |
46,600
+32,100
| +221% | +$5.75M | 0.15% | 92 |
|
|
2019
Q1 | $2.75M | Sell |
14,500
-30,450
| -68% | -$5.81M | 0.15% | 97 |
|
|
2018
Q4 | $8.75M | Buy |
44,950
+8,000
| +22% | +$1.56M | 0.58% | 48 |
|
|
2018
Q3 | $7.66M | Sell |
36,950
-10,950
| -23% | -$2.16M | 0.49% | 58 |
|
|
2018
Q2 | $8.84M | Sell |
47,900
-20,800
| -30% | -$3.68M | 0.75% | 47 |
|
|
2018
Q1 | $11.7M | Sell |
68,700
-13,050
| -16% | -$2.4M | 1.16% | 33 |
|
|
2017
Q4 | $14.2M | Sell |
81,750
-116,895
| -59% | -$20.7M | 1.49% | 23 |
|
|
2017
Q3 | $37M | Buy |
198,645
+34,917
| +21% | +$6.19M | 3.87% | 2 |
|
|
2017
Q2 | $28.2M | Buy |
163,728
+8,278
| +5% | +$1.35M | 3.33% | 2 |
|
|
2017
Q1 | $25.5M | Buy |
155,450
+71,950
| +86% | +$12M | 3.4% | 2 |
|
|
2016
Q4 | $12.2M | Hold |
83,500
| – | – | 2.5% | 10 |
|
|
2016
Q3 | $13.9M | Hold |
83,500
| – | – | 2.52% | 8 |
|
|
2016
Q2 | $12.7M | Sell |
83,500
-19,500
| -19% | -$3.03M | 2.39% | 10 |
|
|
2016
Q1 | $15.4M | Buy |
+103,000
| New | +$15.3M | 2.8% | 6 |
|
Other funds holding AMGN
VCM
VPM
Bellevue Group's AMGN Position: Q1 2026 in Review
Bellevue Group increased its Amgen (AMGN) stake by 1,497% in Q1 2026, buying an estimated $98.7M and bringing the position to 295,358 shares worth $104M. The position accounts for 2.47% of the portfolio, ranked #14.
Bellevue Group first reported a position in AMGN in Q1 2016 and has held it in 41 quarters since. 3,129 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Bellevue Group held 295,358 shares of Amgen worth $104M as of Q1 2026.
- Bellevue Group bought 276,869 Amgen shares in Q1 2026, an estimated $98.7M.
- Amgen made up 2.47% of Bellevue Group's portfolio in Q1 2026, its #14 holding.
- Bellevue Group first reported a position in Amgen in Q1 2016 and has held it in 41 quarters since.
- 3,129 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.